Dennis M. Lanfear - Jun 6, 2021 Form 4 Insider Report for Coherus BioSciences, Inc. (CHRS)

Signature
/s/ McDavid Stilwell, as Attorney-in-Fact for Dennis M. Lanfear
Stock symbol
CHRS
Transactions as of
Jun 6, 2021
Transactions value $
-$283,246
Form type
4
Date filed
6/8/2021, 05:11 PM
Next filing
Nov 23, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CHRS Common Stock Options Exercise $125K +300K +155.23% $0.42* 493K Jun 6, 2021 Direct
transaction CHRS Common Stock Options Exercise $12.9K +31.1K +6.3% $0.42* 524K Jun 8, 2021 Direct
transaction CHRS Common Stock Sale -$421K -31.1K -5.92% $13.56 493K Jun 8, 2021 Direct F3
holding CHRS Common Stock 447K Jun 6, 2021 By Trust F1
holding CHRS Common Stock 87K Jun 6, 2021 By LLC F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CHRS Stock Option (Right to Buy) Options Exercise $0 -300K -90.62% $0.00 31.1K Jun 6, 2021 Common Stock 300K $0.42 Direct F4
transaction CHRS Stock Option (Right to Buy) Options Exercise $0 -31.1K -100% $0.00* 0 Jun 8, 2021 Common Stock 31.1K $0.42 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are held by the Lanfear Revocable Trust, dated January 27, 2004, as restated, of which Reporting Person is a trustee.
F2 These shares are held by Lanfear Capital Advisors, LLC of which Reporting Person is President.
F3 The transaction was executed in multiple trades in prices ranging from $13.55 to $13.61, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
F4 The shares underlying this option are fully vested and exercisable as of the date hereof.